{"filings":[{"id":2033048,"accession_number":"0001140361-26-031028","cik":320017,"company_name":"LISATA THERAPEUTICS, INC.","ticker":"LSTA","form_type":"8-K","filed_at":"2026-08-04T10:01:26+00:00","items":["2.05","5.02","8.01","9.01"],"status":"ready","headline":"Lisata Therapeutics cuts 72% of workforce, sues Kuva Labs over merger breach","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Workforce reduced by ~72% effective immediately; estimated $1.2M in severance costs through Q3 2026.","CMO Dr. Kristen K. Buck terminated without cause; entitled to 12 months salary and bonus plus COBRA.","Company sued Kuva Labs in Delaware Chancery for breach of March 2026 merger agreement, seeking damages.","Retention bonus of $200k approved for SVP James Nisco, contingent on employment through Dec 31, 2026.","Company plans to pursue strategic options to maximize shareholder value."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":30051090.093749993,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1847516,"accession_number":"0001140361-26-029541","cik":320017,"company_name":"LISATA THERAPEUTICS, INC.","ticker":"LSTA","form_type":"8-K","filed_at":"2026-07-24T16:15:36+00:00","items":["1.02","8.01"],"status":"ready","headline":"Lisata Therapeutics terminates merger with Kuva Labs; Kuva failed to secure financing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Merger agreement terminated after Kuva Labs failed to obtain financing to fund tender offer.","Kuva must pay Lisata a $2M termination fee under the agreement.","Lisata reserves rights to seek damages for willful breach; no assurance of recovery.","Board to assess strategic alternatives including reverse merger, business combination, asset sales, or dissolution.","No timetable set for strategic review; no assurance of any transaction."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":30051090.093749993,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1700876,"accession_number":"0001140361-26-028763","cik":320017,"company_name":"LISATA THERAPEUTICS, INC.","ticker":"LSTA","form_type":"8-K","filed_at":"2026-07-17T11:01:28+00:00","items":["1.01","9.01"],"status":"ready","headline":"Lisata Therapeutics extends merger outside date with Kuva Labs to July 21, 2026","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Amendment extends Outside Date from July 17 to July 21, 2026.","Merger agreement originally dated March 6, 2026, with Kuva Labs Inc.","Extension provides additional time to satisfy closing conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":30051090.093749993,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":927640,"accession_number":"0001140361-26-024560","cik":320017,"company_name":"LISATA THERAPEUTICS, INC.","ticker":"LSTA","form_type":"8-K","filed_at":"2026-06-09T11:30:04+00:00","items":["1.01","9.01"],"status":"ready","headline":"Kuva Labs delays tender offer for Lisata to June 10; outside date extended to July 17","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Tender offer commencement deadline extended from June 1 to June 10, 2026; company waives claims for previous delay.","Outside date extended from July 1 to July 17, 2026; Parent may pay $1.5M non-refundable fee to extend to August 17.","Parent acknowledges no committed financing; plans up to $25M in convertible notes from JBA Asset Management only non-binding.","Company waives $250K interim operating payment default in exchange for $150K on June 12 and $100K on June 26.","Lisata covenants not to sue until June 10; termination rights if Parent breaches."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":30051090.093749993,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":758799,"accession_number":"0001140361-26-023397","cik":320017,"company_name":"LISATA THERAPEUTICS, INC.","ticker":"LSTA","form_type":"8-K","filed_at":"2026-06-01T10:03:38+00:00","items":["8.01"],"status":"ready","headline":"Kuva Labs notifies Lisata it will not commence tender offer on June 1 as agreed; deal uncertain","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["On May 31, Kuva Labs told Lisata it will not start the tender offer on June 1 as previously agreed and amended.","No assurance on when or if the tender offer will commence; Kuva is still negotiating financing sources.","Merger Agreement signed March 6, 2026; amendment on May 29 extended start date to June 1.","Parent's failure to commence as agreed raises concern about deal completion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":30051090.093749993,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":748276,"accession_number":"0001140361-26-023336","cik":320017,"company_name":"LISATA THERAPEUTICS, INC.","ticker":"LSTA","form_type":"8-K","filed_at":"2026-05-29T20:50:12+00:00","items":["1.01","9.01"],"status":"ready","headline":"Lisata amends merger: cash per share cut from $5 to $4, CVR increased to up to $3","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Cash consideration reduced from $5.00 to $4.00 per share; CVR now offers up to $3.00 total ($1.25 + $1.75 milestone payments).","Tender offer to commence June 1, 2026; outside date extended from July 1 to July 6, 2026.","First CVR milestone ($1.25) tied to completion/90% enrollment of Phase 2a GBM study; second ($1.75) to NDA filing.","Original CVR was a single $1.00 contingent payment; new structure adds potential $2.00 upside but lowers upfront cash."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":30051090.093749993,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":97973,"accession_number":"0001140361-26-018651","cik":320017,"company_name":"LISATA THERAPEUTICS, INC.","ticker":"LSTA","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Lisata extends tender offer deadline to May 29; Kuva to pay up to $1.1M in expenses","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Tender offer commencement extended from April 13 to May 29, 2026, under amended merger agreement.","Kuva Labs to pay Lisata up to $1.1M via five interim payments: $175k on May 5, $175k on May 7, $250k on May 12, $250k on May 19, $250k on May 26.","Lisata agrees not to sue Kuva until May 29; waives all claims for failure to start offer by April 13 upon commencement and payment of interim amounts.","Waiver terminates if Kuva fails to make any interim payment when due or commits an uncured material breach.","Original merger agreement signed March 6, 2026; deal remains subject to regulatory and stockholder conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":30051090.093749993,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":97972,"accession_number":"0001140361-26-014775","cik":320017,"company_name":"LISATA THERAPEUTICS, INC.","ticker":"LSTA","form_type":"8-K","filed_at":"2026-04-15T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Lisata acquisition in limbo: Kuva Labs delays tender offer, seeks new financing","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Kuva Labs has not yet commenced tender offer for Lisata; deadline extended from April 3 to April 13, 2026.","Kuva seeking alternative financing on more favorable terms; will launch tender only after financing finalized.","Lisata in discussions with Kuva regarding financing and timing; no assurance of commencement or deal completion.","Potential termination of Merger Agreement if tender not commenced; risks include termination fees and litigation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":30051090.093749993,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":97971,"accession_number":"0001140361-26-013070","cik":320017,"company_name":"LISATA THERAPEUTICS, INC.","ticker":"LSTA","form_type":"8-K","filed_at":"2026-04-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Lisata extends tender offer deadline to April 13, 2026 per waiver","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Deadline to commence tender offer moved from April 3 to April 13, 2026.","Waiver signed April 2 by Lisata, Kuva Labs Inc., and Kuva Acquisition Corp.","All other Merger Agreement terms (March 6, 2026) remain unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":30051090.093749993,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":113199,"accession_number":"0000320017-26-000020","cik":320017,"company_name":"LISATA THERAPEUTICS, INC.","ticker":"LSTA","form_type":"8-K","filed_at":"2026-03-09T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Lisata to be acquired by Kuva Labs for $5.00 per share plus contingent $1.00 CVR","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Kuva Labs will acquire all Lisata common shares for $5.00 cash plus one non-tradeable CVR potentially paying $1.00 upon FDA filing for certepetide.","CVR milestone: payable if NDA is filed/accepted for certepetide within 7 years of closing; Parent must use commercially reasonable efforts.","Unanimous board recommendation; tender offer with minimum tender condition of majority of outstanding shares (including rollover shares).","Termination fee of $2M payable by either party under certain circumstances; no financing condition to the offer.","In-the-money options, restricted stock, and RSUs cashed out at Closing Amount plus CVR; ESPP terminated at closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":30051090.093749993,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":113198,"accession_number":"0000320017-26-000012","cik":320017,"company_name":"LISATA THERAPEUTICS, INC.","ticker":"LSTA","form_type":"8-K","filed_at":"2026-02-27T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Lisata and Kuva extend exclusive negotiation deadline to March 7, 2026 for acquisition","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Amendment to binding term sheet extends expiration from Feb 28 to March 7, 2026.","Kuva Labs to acquire Lisata via tender offer and short-form merger under Section 251(h).","No other changes to term sheet; parties continue negotiating purchase agreement.","Acquisition remains subject to tender offer conditions and regulatory approvals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":30051090.093749993,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":113197,"accession_number":"0000320017-26-000008","cik":320017,"company_name":"LISATA THERAPEUTICS, INC.","ticker":"LSTA","form_type":"8-K","filed_at":"2026-01-27T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Lisata Therapeutics terminates exclusive license for certepetide with Qilu Pharmaceutical","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Mutual termination of 2021 License and Collaboration Agreement with Qilu, effective January 23, 2026.","Agreement covered research, development, and commercialization of certepetide (CEND-1) in Greater China.","Lisata was eligible for up to $200M in milestone payments and 10%-15% royalties on net sales.","Termination does not affect obligations accrued prior to termination or certain surviving provisions.","No immediate financial impact disclosed; company loses future milestone/royalty potential."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":30051090.093749993,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":113196,"accession_number":"0000320017-26-000006","cik":320017,"company_name":"LISATA THERAPEUTICS, INC.","ticker":"LSTA","form_type":"8-K","filed_at":"2026-01-21T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Lisata to be acquired by Kuva Labs for $4.00 cash/share + up to $2 CVRs; ~85% premium","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["All-cash tender offer at $4.00/share plus two non-tradeable CVRs worth up to $2/share tied to certepetide milestones.","Cash portion represents ~85% premium over last close; total potential consideration ~180% premium.","Kuva has committed financing and will not condition offer on funding; break fee of $2 million for certain failures.","Definitive purchase agreement targeted by Feb 27, 2026; boards of both companies unanimously approved term sheet.","Rollover shares may be contributed to Kuva in exchange for equity, and standstill restricts Kuva for 12 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":30051090.093749993,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":129585,"accession_number":"0000320017-25-000069","cik":320017,"company_name":"LISATA THERAPEUTICS, INC.","ticker":"LSTA","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Lisata reports Q3 2025 net loss $4.2M; cash runway into Q1 2027 with new partnerships","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $4.2M vs $4.9M in Q3 2024; operating expenses down 17% to $4.4M.","Cash and equivalents $19.0M; management projects funding operations into Q1 2027.","ASCEND mPDAC trial final data expected Q1 2026; BOLSTER topline data due Q4 2025.","Licensed certepetide to Catalent for ADC platform; partnered with GATC Health for AI drug discovery.","Preliminary CENDIFOX data showed 70% pathologic partial response and 60% 2-year OS in PDAC cohort."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":70000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":30051090.093749993,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":129584,"accession_number":"0000320017-25-000066","cik":320017,"company_name":"LISATA THERAPEUTICS, INC.","ticker":"LSTA","form_type":"8-K","filed_at":"2025-10-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Lisata posts corporate presentation for conferences; no material updates disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Filed 8-K for a slide presentation dated October 14, 2025, used at investor and industry conferences.","Presentation provides general company overview and pipeline status; no new financial or clinical data.","No guidance changes, no earnings release, and no material events reported in the filing.","Confidence limited because the presentation content was not fully provided in the filing excerpt."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":30051090.093749993,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":129583,"accession_number":"0000320017-25-000063","cik":320017,"company_name":"LISATA THERAPEUTICS, INC.","ticker":"LSTA","form_type":"8-K","filed_at":"2025-10-08T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Lisata grants Catalent non-exclusive license for certepetide ADC payload; up to $10.5M milestones","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Granted Catalent non-exclusive license to use certepetide as ADC payload in SMARTag platform; Catalent assumes all R&D/commercial costs.","Eligible for up to $10.5M in development milestone payments plus tiered revenue sharing on future sales/partnerships.","Also entitled to portion of sublicense consideration received by Catalent.","Catalent may terminate agreement on 30 days notice; also grants Lisata ROFN for out-licensing of resulting assets."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":30051090.093749993,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":146160,"accession_number":"0000320017-25-000059","cik":320017,"company_name":"LISATA THERAPEUTICS, INC.","ticker":"LSTA","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Lisata Q2 net loss $4.7M, cash $22M; certepetide trials advancing with multiple data milestones ahead","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $4.7M vs $5.0M in Q2 2024; revenue of $70K from Catalent license fee.","Cash, equivalents and securities total $22.0M; runway into Q4 2026 funds all active trials to next data milestone.","ASCEND Phase 2b Cohort B showed positive PFS and ORR signal; final data expected late 2025.","BOLSTER Phase 2a first-line CCA enrollment complete; topline data due Q4 2025.","USPTO issued new composition-of-matter patent for certepetide (U.S. 12,351,653) extending protection to March 2040."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":70000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":30051090.093749993,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":146159,"accession_number":"0000320017-25-000048","cik":320017,"company_name":"LISATA THERAPEUTICS, INC.","ticker":"LSTA","form_type":"8-K","filed_at":"2025-07-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Lisata Therapeutics granted US composition-of-matter patent for certepetide expiring 2040","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["U.S. Patent No. 12,351,653 covers certepetide's chemical structure and pharmacokinetic properties.","Patent expires March 2040 with opportunity for patent term extension.","CEO states strengthened IP estate and long-term market exclusivity for certepetide.","Patent includes claims for treating solid tumor cancers and methods of manufacture."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":30051090.093749993,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":164481,"accession_number":"0000320017-25-000043","cik":320017,"company_name":"LISATA THERAPEUTICS, INC.","ticker":"LSTA","form_type":"8-K","filed_at":"2025-06-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Positive Cohort B ASCEND data: 6M PFS 60.8% (certepetide) vs 25% (placebo)","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cohort B: median PFS 7.5 months (certepetide) vs 4.7 months (placebo); ORR 45.2% vs 19%.","Median OS 10.32 months (certepetide) vs 9.23 months (placebo); safety profile attractive.","Cohort B regimen (two doses of certepetide) showed clinically meaningful improvement over Cohort A.","Full data from both cohorts expected later 2025; presented at ESMO GI on 2 July 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":30051090.093749993,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":164480,"accession_number":"0000320017-25-000039","cik":320017,"company_name":"LISATA THERAPEUTICS, INC.","ticker":"LSTA","form_type":"8-K","filed_at":"2025-06-17T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Lisata extends cash runway from Q3 2026 to Q4 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company now expects current cash to fund operations into Q4 2026, versus prior Q3 2026 estimate.","As of March 31, 2025, cash, cash equivalents and marketable securities were approximately $25.8 million.","Revised guidance based on existing and planned activities; no other material changes disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":30051090.093749993,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":164479,"accession_number":"0000320017-25-000037","cik":320017,"company_name":"LISATA THERAPEUTICS, INC.","ticker":"LSTA","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Lisata Therapeutics raises CEO salary to $717,229, CMO salary to $599,342 in amended employment agreements","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO David Mazzo base salary increased to $717,229 from $633,032; $12,000 non-accountable expense allowance removed.","CMO Kristen Buck base salary increased to $599,342 from $550,000.","Amended severance terms for CEO, CMO, CAO Nisco, and GC Imam; includes COBRA reimbursement changes and Section 409A clarifications.","Change in Control definition amended to include shareholder-approved complete liquidation, subject to 409A requirements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":30051090.093749993,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":164478,"accession_number":"0000320017-25-000033","cik":320017,"company_name":"LISATA THERAPEUTICS, INC.","ticker":"LSTA","form_type":"8-K","filed_at":"2025-06-10T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Lisata shareholders re-elect Azab, Klosk; approve ESPP, auditor, say-on-pay, one-year frequency","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Re-elected Mohammad Azab (3,809,977 for) and Steven Klosk (3,788,000 for) as Class III directors to 2028.","Approved amendment to 2017 ESPP increasing shares from 113,333 to 158,333 (3,523,229 for, 294,116 against, 378,495 abstain).","Ratified Grant Thornton LLP as independent auditor for FY2025 (6,226,674 for, 64,171 against, 136,348 abstain).","Non-binding advisory votes: approved executive compensation (3,496,571 for) and selected one-year frequency for future say-on-pay votes (3,967,202 for one year)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":30051090.093749993,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":164477,"accession_number":"0000320017-25-000028","cik":320017,"company_name":"LISATA THERAPEUTICS, INC.","ticker":"LSTA","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Lisata Q1 net loss $4.7M; cash $25.8M; ASCEND Cohort B oral at ESMO-GI Jul 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $4.7M for Q1 2025, vs $5.4M in Q1 2024; operating expenses down 11% to $5.8M.","Cash, equivalents, and marketable securities $25.8M as of Mar 31, 2025; runway into Q3 2026.","Cohort B of ASCEND trial (mPDAC) accepted for oral presentation at ESMO-GI July 2025; final analysis pending.","BOLSTER trial in first-line cholangiocarcinoma fully enrolled; topline data anticipated mid-2025.","Qilu's Phase 2 certepetide trial in China complete; Phase 3 start triggers $10M milestone payment."],"consensus_eps_estimate":-0.5406,"consensus_eps_actual":-0.55,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q1","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":30051090.093749993,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":182233,"accession_number":"0000320017-25-000010","cik":320017,"company_name":"LISATA THERAPEUTICS, INC.","ticker":"LSTA","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Lisata Therapeutics reports 2024 net loss $20M, cash $31.2M; promising Phase 2b pancreatic cancer data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1.0M from Kuva license (vs $0 in 2023); operating expenses down 8.9% to $23.4M.","Net loss $20.0M vs $20.8M in 2023; cash, equivalents & securities $31.2M; runway into Q2 2026.","Phase 2b ASCEND (mPDAC) showed positive OS trend; four complete responses in certepetide arm, none in placebo.","BOLSTER (cholangiocarcinoma) first-line enrollment complete; topline data expected mid-2025.","iLSTA (PDAC+immunotherapy) 27 of 30 enrolled; enrollment completion H1 2025."],"consensus_eps_estimate":-0.7752,"consensus_eps_actual":-2.4,"consensus_revenue_estimate":null,"consensus_revenue_actual":1000000.0,"consensus_period":"2024-FY","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":30051090.093749993,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":182232,"accession_number":"0000320017-25-000004","cik":320017,"company_name":"LISATA THERAPEUTICS, INC.","ticker":"LSTA","form_type":"8-K","filed_at":"2025-01-23T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Lisata reports Phase 2 ASCEND Cohort A: mOS 12.68 vs 9.72 months; 4 complete responses","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cohort A: median OS of 12.68 months for certepetide plus chemo vs 9.72 months for placebo plus chemo.","Complete responses: 4 of 65 (6.2%) in certepetide group; 0 of 28 in placebo group.","Median PFS was 5.5 months in both arms; 6-month PFS trend favored certepetide.","Cohort B (two-dose regimen) data expected in coming months; full data from both cohorts to follow.","Lisata plans to advance certepetide to Phase 3 in early 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":30051090.093749993,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":198860,"accession_number":"0000320017-24-000061","cik":320017,"company_name":"LISATA THERAPEUTICS, INC.","ticker":"LSTA","form_type":"8-K","filed_at":"2024-12-03T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Lisata Therapeutics licenses certepetide to Kuva Labs for solid tumor imaging","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Upfront cash license fee of $1.0M payable over 12 months in four installments.","Development milestones up to $1.5M; commercial milestones up to $17.5M; 5% royalty on net sales.","Kuva assumes full R&D and commercialization costs; Lisata to supply certepetide for clinical and commercial use.","Partnership combines Lisata's certepetide with Kuva's NanoMark imaging technology for solid tumors.","Agreement effective November 30, 2024; Kuva may terminate on 60-day notice."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":30051090.093749993,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":198859,"accession_number":"0000320017-24-000057","cik":320017,"company_name":"LISATA THERAPEUTICS, INC.","ticker":"LSTA","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Lisata Therapeutics Q3 2024 net loss $4.9M; cash runway into early 2026; multiple trial updates","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $4.9M in Q3 2024, improved from $5.3M loss in Q3 2023.","Cash, cash equivalents and marketable securities of $35.9M as of Sep 30, 2024; funds operations into early 2026.","Phase 2b ASCEND trial (mPDAC) Cohort A interim data expected at ASCO GI in Jan 2025; Cohort B data mid-2025.","BOLSTER Phase 2a first-line cholangiocarcinoma enrollment complete ahead of plan; topline data mid-2025; second-line cohort added.","Entered research collaborations for certepetide: endometriosis (Univ. of Cincinnati) and melanoma (Valo Therapeutics)."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.85,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":30051090.093749993,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":214902,"accession_number":"0000320017-24-000049","cik":320017,"company_name":"LISATA THERAPEUTICS, INC.","ticker":"LSTA","form_type":"8-K","filed_at":"2024-08-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Lisata Therapeutics Q2 2024 net loss $5.0M; ASCEND Phase 2b top-line data expected Q4 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $5.0M in Q2 2024 vs $4.0M in Q2 2023; operating expenses down 19.7% to $5.5M.","Cash & equivalents $38.3M; funding into early 2026 covering all active trials to data milestones.","Phase 2b ASCEND trial (certepetide + chemo in mPDAC) top-line results from 95-patient Cohort A on track for Q4 2024.","BOLSTER Phase 2a in 1L cholangiocarcinoma fully enrolled ahead of plan; topline data mid-2025; 2L cohort added.","Certepetide received U.S. FDA Orphan Drug and Rare Pediatric Disease designations for osteosarcoma in H1 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":30051090.093749993,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":234086,"accession_number":"0000320017-24-000034","cik":320017,"company_name":"LISATA THERAPEUTICS, INC.","ticker":"LSTA","form_type":"8-K","filed_at":"2024-06-27T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Lisata shareholders approve all six proposals at 2024 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Re-elected Class II directors Brown, Henson, and Mazzo; votes ranged from 3.15M to 3.26M for.","Approved 2018 Equity Plan amendment adding 600k shares and a 3-year evergreen clause (5% or board-set).","Approved ESPP increase from 68,333 to 113,333 shares; 3.06M for, 131k against.","Ratified Grant Thornton as auditor for FY2024; 3.71M for, 401k against, no broker non-votes.","Non-binding advisory vote on executive compensation passed with 3.09M for, 417k against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":30051090.093749993,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":234085,"accession_number":"0000320017-24-000029","cik":320017,"company_name":"LISATA THERAPEUTICS, INC.","ticker":"LSTA","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Lisata Q1 net loss $5.4M; ASCEND Phase 2b data on track for Q4 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents and marketable securities $43.3M as of Mar 31, 2024; funding operations into early 2026.","Net loss $5.4M vs $6.2M in Q1 2023; operating expenses $6.6M, down 3.6% YoY.","Top-line data from pivotal Phase 2b ASCEND trial (mPDAC) expected Q4 2024; full data set mid-2025.","Received FDA Orphan Drug and Rare Pediatric Disease designations for certepetide in osteosarcoma.","BOLSTER (cholangiocarcinoma) enrollment completion expected Q3 2024; CENDIFOX on track for year-end 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.65,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":30051090.093749993,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":234084,"accession_number":"0000320017-24-000013","cik":320017,"company_name":"LISATA THERAPEUTICS, INC.","ticker":"LSTA","form_type":"8-K","filed_at":"2024-04-17T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Lisata appoints James Nisco as SVP, Finance & Treasury and CAO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["James Nisco appointed Senior Vice President, Finance and Treasury and Chief Accounting Officer effective April 15, 2024.","Nisco will serve as principal financial officer and principal accounting officer.","Annual base salary set at $350,000 with a short-term incentive bonus target of 35% of base.","Nisco previously served as Vice President of Finance & Treasury since August 2020, an internal promotion.","No family relationships with directors/executives; no reportable transactions under Item 404."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":30051090.093749993,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":252029,"accession_number":"0000320017-24-000006","cik":320017,"company_name":"LISATA THERAPEUTICS, INC.","ticker":"LSTA","form_type":"8-K","filed_at":"2024-02-29T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Lisata Therapeutics reports FY2023 net loss $20.8M; cash $50.5M; ASCEND trial on track for Q4 2024 data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $20.8M for FY2023 vs $54.2M in FY2022; operating expenses $25.7M (down 55% YoY).","Cash, cash equivalents, and marketable securities of $50.5M; runway projected into early 2026.","Phase 2b ASCEND trial in mPDAC fully enrolled; top-line data expected Q4 2024; complete data mid-2025.","R&D expenses $12.7M vs $13.1M prior year; G&A expenses $13.0M vs $14.1M.","Multiple Phase 2a trials ongoing (BOLSTER, CENDIFOX, iLSTA, GBM); Qilu licensee progressing in China."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":30051090.093749993,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":269563,"accession_number":"0000320017-23-000062","cik":320017,"company_name":"LISATA THERAPEUTICS, INC.","ticker":"LSTA","form_type":"8-K","filed_at":"2023-11-02T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Lisata Q3 net loss $5.3M; ASCEND ~95% enrolled, BOLSTER first patients treated","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $5.3M in Q3 2023 (vs $37.4M prior year which included $30.4M merger costs); cash $54.4M.","ASCEND study (~95% enrollment) received positive interim futility analysis; topline data from Cohort A expected as early as Q4 2024.","First patients treated in BOLSTER basket trial for head and neck and cholangiocarcinoma cohorts.","Orphan drug designations granted for LSTA1 in malignant glioma (U.S.) and pancreatic cancer (EU).","Cash runway into early 2026; expected to fund all ongoing trials through data."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.92,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":30051090.093749993,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":286555,"accession_number":"0000320017-23-000054","cik":320017,"company_name":"LISATA THERAPEUTICS, INC.","ticker":"LSTA","form_type":"8-K","filed_at":"2023-08-14T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Lisata Q2 net loss $4.0M, extends cash runway to Q1 2026; tech transfer deal for TPN platform","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $4.0M in Q2 2023 vs $6.6M in Q2 2022, down 40% due to $2.2M NJ tax credit.","Cash and securities $57.6M; projected runway into Q1 2026 based on capital conservation measures.","Signed technology transfer agreement for TPN platform with Impilo Therapeutics; receives equity stake, no future capital commitment.","LSTA1 progress: ASCEND Phase 2b enrollment >70% target; BOLSTER trial open; iLSTA initiated in Australia.","FDA granted orphan designation for LSTA1 in malignant glioma; GBM trial planned for Q4 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":30051090.093749993,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":286554,"accession_number":"0000320017-23-000037","cik":320017,"company_name":"LISATA THERAPEUTICS, INC.","ticker":"LSTA","form_type":"8-K","filed_at":"2023-07-11T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Lisata Therapeutics announces retirement of director Erkki Ruoslahti; remains advisor","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Erkki Ruoslahti resigned from the Board of Directors effective July 11, 2023.","He will continue as a scientific advisor to the Company.","Ruoslahti cited confidence in LSTA1 progress and reduced international travel as reasons.","He is the scientific founder of the CendR Platform and a Lasker Prize winner.","No replacement announced; board size unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":30051090.093749993,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":306463,"accession_number":"0000320017-23-000031","cik":320017,"company_name":"LISATA THERAPEUTICS, INC.","ticker":"LSTA","form_type":"8-K","filed_at":"2023-06-14T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Lisata shareholders re-elect two Class I directors, approve equity plan amendments","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Re-elected Cynthia L. Flowers and Erkki Ruoslahti as Class I directors to 2026 term; 3.76M and 3.77M votes for respectively.","Approved amendment to 2018 Equity Incentive Plan adding 400,000 shares; 3.53M for.","Approved amendment to 2017 ESPP increasing shares to 68,333; 3.76M for.","Ratified Grant Thornton as independent auditor for FY2023; 5.68M for.","Non-binding advisory approval of executive compensation; 3.71M for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":30051090.093749993,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":306462,"accession_number":"0000320017-23-000027","cik":320017,"company_name":"LISATA THERAPEUTICS, INC.","ticker":"LSTA","form_type":"8-K","filed_at":"2023-05-09T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Lisata Q1 net loss $6.2M; cash $61.1M; LSTA1 advances but LSTA201 disappoints","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 net loss $6.2M vs $4.2M YoY; R&D $3.2M, G&A $3.7M.","Cash, equivalents & marketable securities $61.1M as of Mar 31; plus $2.2M non-dilutive NJ tax credit received Q2.","LSTA1: first patient dosed in iLSTA trial for pancreatic cancer; basket trial in solid tumors planned before end of Q2 2023.","LSTA201 for diabetic kidney disease showed safety but no consistent kidney function improvement; development only with partner.","HONEDRA (LSTA12) for critical limb ischemia in Japan: pre-consultation with PMDA; seeking partner."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.77,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":30051090.093749993,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":306461,"accession_number":"0000320017-23-000021","cik":320017,"company_name":"LISATA THERAPEUTICS, INC.","ticker":"LSTA","form_type":"8-K","filed_at":"2023-05-01T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Lisata Therapeutics eliminates President & CBO role, terminates David Slack effective May 1, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Position of President and Chief Business Officer eliminated; David Slack terminated immediately.","Slack resigned from Board of Directors per employment agreement.","Severance: $478,400 over 12 months; bonus of $239,200 (50% of base salary) paid over same period.","Additional lump sum of $24,134 for earned pay, PTO, and expenses; COBRA assistance provided.","Vested option exercise period extended to three years post-termination or remaining term, whichever shorter."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":30051090.093749993,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":325594,"accession_number":"0000320017-23-000010","cik":320017,"company_name":"LISATA THERAPEUTICS, INC.","ticker":"LSTA","form_type":"8-K","filed_at":"2023-03-30T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Lisata Therapeutics reports FY2022 financial results and provides business update","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for FY2022 was $54.2 million, including $30.4 million non-routine merger-related IPR&D expense.","Cash, cash equivalents and marketable securities totaled $69.2 million as of December 31, 2022.","LSTA1 Phase 2b ASCEND study in pancreatic cancer is ongoing; basket trial in other solid tumors planned for H1 2023.","HONEDRA for critical limb ischemia is in pre-consultation with Japan's PMDA; partner search continues.","XOWNA development suspended; LSTA201 proof-of-concept study did not show consistent kidney function improvement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":30051090.093749993,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":325593,"accession_number":"0000320017-23-000003","cik":320017,"company_name":"LISATA THERAPEUTICS, INC.","ticker":"LSTA","form_type":"8-K","filed_at":"2023-02-06T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"Lisata's LSTA201 trial in diabetic kidney disease fails to show consistent kidney function improvement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary unaudited cash, equivalents and marketable securities of ~$69.2M as of Dec 31, 2022.","Phase 1b trial of LSTA201 (CD34+ cell therapy) in 6 DKD patients tolerated but no consistent kidney function improvement.","Company will evaluate data and determine next steps; no further clinical study committed.","Corporate presentation attached as Exhibit 99.1 for investor conference use."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":30051090.093749993,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":343345,"accession_number":"0000320017-22-000101","cik":320017,"company_name":"LISATA THERAPEUTICS, INC.","ticker":"LSTA","form_type":"8-K","filed_at":"2022-11-10T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Lisata Therapeutics Q3 net loss widens to $37.4M on merger costs; cash $75.5M; LSTA1 trials on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $37.4M (Q3 2022) vs $6.9M (Q3 2021), driven by merger-related expenses and stock compensation.","Cash, equivalents and marketable securities $75.5M as of Sept 30, 2022.","R&D expenses $3.4M (-18% YoY) due to XOWNA FREEDOM trial suspension; G&A $3.9M (+39%) on merger costs.","LSTA1 Phase 2b ASCEND and Phase 1b/2 CENDIFOX trials on track to complete enrollment late 2023/early 2024.","HONEDRA (CLI) pre-consultation with PMDA ongoing; XOWNA (CMD) development paused pending strategic partner."],"consensus_eps_estimate":null,"consensus_eps_actual":-11.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":30051090.093749993,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":343344,"accession_number":"0001140361-22-037226","cik":320017,"company_name":"LISATA THERAPEUTICS, INC.","ticker":"LSTA","form_type":"8-K/A","filed_at":"2022-10-14T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Lisata files audited FY2020-2021 financials of acquired Cend Therapeutics","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Audited financial statements of Cend for FY2020 and FY2021 filed as Exhibit 99.1.","Consent of independent auditor WithumSmith+Brown, PC filed as Exhibit 23.1.","This amendment fulfills the remaining financial statement requirements for the September 2022 merger.","No other changes were made to the initial Form 8-K reporting the merger completion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":30051090.093749993,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":343343,"accession_number":"0001140361-22-036093","cik":320017,"company_name":"LISATA THERAPEUTICS, INC.","ticker":"LSTA","form_type":"8-K/A","filed_at":"2022-10-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Lisata provides financials of acquired Cend; CEND-1 in Phase 2b for pancreatic cancer","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Merger of Cend into Lisata completed Sep 14, 2022; this amendment provides historical and pro forma financials of Cend.","Cend's lead drug CEND-1 (iRGD peptide) in Phase 2b for 1L metastatic PDAC; Phase 1b showed promising safety and efficacy.","Cend collaboration with Qilu Pharma for Greater China: $10M upfront, up to $225M in milestones, tiered royalties 10-15%.","Cend recorded net income in 2021 from one-time license payment, but otherwise incurred losses since inception.","Unaudited interim financials of Cend as of June 30, 2022 and pro forma combined financials of Lisata are filed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":30051090.093749993,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":359887,"accession_number":"0000320017-22-000094","cik":320017,"company_name":"LISATA THERAPEUTICS, INC.","ticker":"LSTA","form_type":"8-K","filed_at":"2022-09-29T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Lisata regains Nasdaq minimum bid price compliance; delisting risk removed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received Nasdaq deficiency letter on Feb 18, 2022 for bid price below $1.00.","Granted initial 180-day period ending Aug 17, 2022, then second period to Feb 13, 2023.","On Sept 29, 2022, notified compliance regained after 10 consecutive days at $1.00+.","Nasdaq confirmed the matter is now closed.","Stock ticker LSTA remains listed on Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":30051090.093749993,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":359886,"accession_number":"0000320017-22-000085","cik":320017,"company_name":"LISATA THERAPEUTICS, INC.","ticker":"LSTA","form_type":"8-K","filed_at":"2022-09-22T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Lisata halts XOWNA FREEDOM Trial; development now contingent on partner","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2b FREEDOM Trial of XOWNA (autologous CD34+ cells) suspended May 2022 due to COVID enrollment challenges and heterogeneity.","Interim analysis of first 20 patients with 6-month follow-up completed; board decided redesigned trial is needed but prohibitively expensive alone.","XOWNA development will only continue if a strategic partner is identified and secured to fund a redesigned trial.","No assurance that a partner can be found or that acceptable terms will be reached."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":30051090.093749993,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":359885,"accession_number":"0001140361-22-033411","cik":320017,"company_name":"LISATA THERAPEUTICS, INC.","ticker":"LSTA","form_type":"8-K","filed_at":"2022-09-15T23:59:59+00:00","items":["2.01","3.03","5.02","5.03","7.01","9.01"],"status":"ready","headline":"Lisata Therapeutics formed via Caladrius-Cend merger; ~$76M cash, ticker LSTA","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Merger closed 9/15/22: Caladrius issued 0.5338 shares per Cend share after 1:15 reverse split; post-merger shares ~7.82M.","Former Caladrius stockholders own ~52%, former Cend stockholders ~48% of combined company.","Combined cash and investments ~$76M; focus on CendR Platform oncology pipeline and existing programs.","Name changed to Lisata Therapeutics; ticker LSTA on Nasdaq; former ticker CLBS discontinued.","Board expanded with four Cend designees; David Slack named President & CBO; leadership team includes CEO David Mazzo."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":30051090.093749993,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":359884,"accession_number":"0000320017-22-000079","cik":320017,"company_name":"LISATA THERAPEUTICS, INC.","ticker":"LSTA","form_type":"8-K","filed_at":"2022-09-14T23:59:59+00:00","items":["5.03","5.07","8.01","9.01"],"status":"ready","headline":"Caladrius stockholders approve merger with Cend Therapeutics, 1:15 reverse split, name change to Lisata Therapeutics","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Merger with Cend approved: 25,973,235 for, 2,912,622 against, 172,676 abstain.","Reverse stock split at 1:15 ratio approved: 31,343,168 for, 7,665,240 against.","Name change to Lisata Therapeutics approved: 34,861,858 for, 4,003,401 against.","Merger close expected Sep 15, 2022; combined company to trade as LSTA on Nasdaq.","Board set reverse split ratio at 1:15; effective Sep 14, 2022 at 5:00 PM ET."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":30051090.093749993,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":359883,"accession_number":"0000320017-22-000071","cik":320017,"company_name":"LISATA THERAPEUTICS, INC.","ticker":"LSTA","form_type":"8-K","filed_at":"2022-08-19T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Caladrius receives Nasdaq extension to Feb 13, 2023 to regain $1 bid price compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company failed to meet $1 minimum bid price by Aug 17, 2022 initial compliance deadline.","Nasdaq granted extension to Feb 13, 2023; requires closing bid of $1+ for 10 consecutive days.","If compliance not demonstrated by Feb 13, 2023, delisting notice will be issued.","Company may appeal delisting determination, but success cannot be assured."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":30051090.093749993,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":359882,"accession_number":"0000320017-22-000061","cik":320017,"company_name":"LISATA THERAPEUTICS, INC.","ticker":"LSTA","form_type":"8-K","filed_at":"2022-08-05T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Caladrius Q2 net loss $6.6M; merger with Cend on track for Q3 2022 forming Lisata Therapeutics","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $6.6M vs $5.7M YoY; cash $73M after $10M Cend investment.","Merger with Cend expected to close Q3 2022, pending stockholder approval; new ticker LSTA.","HONEDRA pre-consultation with PMDA; XOWNA FREEDOM trial enrollment suspended, interim analysis in Q3.","CLBS201 DKD trial fully enrolled (6 patients), top-line data expected Q1 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":30051090.093749993,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":378758,"accession_number":"0000320017-22-000046","cik":320017,"company_name":"LISATA THERAPEUTICS, INC.","ticker":"LSTA","form_type":"8-K","filed_at":"2022-05-23T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Caladrius suspends enrollment in Phase 2b FREEDOM Trial of XOWNA; interim analysis expected Aug 2022","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Enrollment paused in 105-patient double-blind placebo-controlled FREEDOM Trial; only ~35 patients enrolled to date.","Interim analysis of first 20+ patients with 6-month follow-up data to evaluate efficacy/safety and effect size.","Results due August 2022; next development steps for XOWNA to be announced by year-end 2022.","Causes: COVID-19, supply shortages of catheters/contrast agent, and discontinuation of specified diagnostic equipment.","CEO cites alternative development plan needed; prior timeline of >4 years to complete deemed not viable."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":30051090.093749993,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-05-23T23:59:59+00:00|378758"}